Centessa Pharmaceuticals plc
CNTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -144.3% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -174.2% | – |
| EPS Diluted | -0.41 | -0.38 | -0.2 | -0.84 |
| % Growth | -7.9% | -90% | 76.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |